Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11921121 | 1.00 | EPHX1 (0.51) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL224929 | 1.00 | EPHX1 (0.51) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL2977422 | 0.86 | DRD2 (0.48) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL2977423 | 0.86 | DRD2 (0.48) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL34465370 | 0.86 | BTK (0.48) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL15662556 | 0.86 | BTK (0.48) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL8074670 | 0.85 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL28984107 | 0.85 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL20051778 | 0.85 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL28984106 | 0.85 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171567-B1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250100995-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2025-03-27 | — | — | US | disclosed |
| US-20240374591-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2024-11-14 | — | — | US | disclosed |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| US-12103920-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-10-01 | — | — | US | disclosed |
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20080103140-A1 | trans-N-{4-[2-[4-(indan-4-yl)-piperazin-1-yl]-ethyl]-cyclohexyl}-acetamidethe; highest affinity to D3 receptor; no disadvantages of each individual receptor action; antidepressant, anxiolitic agent, cognition activator; psychoses, schizophrenia, drug (alcohol, cocaine and nicotine) abuse, hyperactivity | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-01 | — | — | US | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070185148-A1 | M3 muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1119563-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| EP-1086084-A1 | TETRAISOQUINOLOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000021951-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999059974-A1 | TETRAISOQUINOLOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12103920-B2 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | CRBN, AR, ESRRA | EPHX1 3920/4885DRD2 548/4885BTK 4267/4885 |
| US-20250100995-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | EPHX1 3905/4885DRD2 842/4885BTK 4329/4885 |
| US-20240374591-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | EPHX1 3980/4885DRD2 640/4885BTK 4192/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | EPHX1 2182/4885DRD2 16/4885BTK 3933/4885 |
| US-20080103140-A1 | trans-N-{4-[2-[4-(indan-4-yl)-piperazin-1-yl]-ethyl]-cyclohexyl}-acetamidethe; highest affinity to D3 receptor; no disadvantages of each individual receptor action; antidepressant, anxiolitic agent, cognition activator; psychoses, schizophrenia, drug (alcohol, cocaine and nicotine) abuse, hyperactivity | CHRNA3, HTR3A, DRD2 | EPHX1 2803/4885DRD2 3/4885BTK 4271/4885 |
| US-20070185148-A1 | M3 muscarinic acetylchoine receptor antagonists | CHRM3, CHRM2, CHRM5 | EPHX1 3027/4885DRD2 950/4885BTK 4857/4885 |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, SHBG | EPHX1 3697/4885DRD2 596/4885BTK 4309/4885 |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | EPHX1 3920/4885DRD2 548/4885BTK 4267/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | EPHX1 2775/4885DRD2 4732/4885BTK 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.